Beta-blockers and COPD: the show must go on. Issue 3 (September 2016)

• Record Type: Journal Article
• Authors: Lopez-Campos, Jose Luis; Márquez-Martín, Eduardo; Casanova, Ciro
• Is Part Of: European respiratory journal. Volume 48:Issue 3(2016)
• Page Start: 600
• Page End: 603
• Publication Date: 2016-09
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01222-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

Identification of comorbidities is now recognised as one of the pillars for a comprehensive clinical evaluation in chronic obstructive pulmonary disease (COPD) [1]. Specifically, the burden of coexisting cardiovascular disease in COPD has gained significant attention, with specific algorithms being developed for its clinical detection [2]. The relationship between the heart and COPD is of clinical relevance not only for the well-documented relationship between the two organs [3], but also for the potential mutual influence of treatments. The interactions between oral beta-blockers and inhaled β-adrenergic drugs pose significant challenges for clinicians involved in the management of patients with chronic cardiorespiratory conditions. In particular, the use of beta-blockers in COPD remains the subject of ongoing controversy [4]. Current evidence on beta-blockers efficacy and safety in COPD is encouraging but limited with future studies needed http://ow.ly/IaNL301YANI